{"id":4234,"date":"2026-03-05T11:14:51","date_gmt":"2026-03-05T11:14:51","guid":{"rendered":"https:\/\/nhsdorset.nhs.uk\/medicines\/?page_id=4234"},"modified":"2026-03-31T12:15:28","modified_gmt":"2026-03-31T11:15:28","slug":"insulin-aspart","status":"publish","type":"page","link":"https:\/\/nhsdorset.nhs.uk\/medicines\/value\/insulin-aspart\/","title":{"rendered":"Insulin aspart biosimilar switch"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1310.4px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span class=\"TextRun SCXW79299778 BCX8\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"none\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW79299778 BCX8\">Trurapi<\/span><span class=\"NormalTextRun SCXW79299778 BCX8\"> biosimilar as the best value preferred insulin aspart pre-filled pen device.<\/span><\/span><\/p>\n<\/div><div class=\"accordian fusion-accordian\" style=\"--awb-border-size:1px;--awb-icon-size:18px;--awb-content-font-size:var(--awb-typography4-font-size);--awb-icon-alignment:left;--awb-hover-color:var(--awb-color2);--awb-border-color:var(--awb-color3);--awb-background-color:var(--awb-color1);--awb-divider-color:var(--awb-color3);--awb-divider-hover-color:var(--awb-color3);--awb-icon-color:var(--awb-color5);--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);--awb-icon-box-color:var(--awb-color5);--awb-toggle-hover-accent-color:var(--awb-color4);--awb-toggle-active-accent-color:var(--awb-color4);--awb-title-font-family:var(--awb-typography1-font-family);--awb-title-font-weight:var(--awb-typography1-font-weight);--awb-title-font-style:var(--awb-typography1-font-style);--awb-title-font-size:20px;--awb-content-font-family:var(--awb-typography4-font-family);--awb-content-font-weight:var(--awb-typography4-font-weight);--awb-content-font-style:var(--awb-typography4-font-style);\"><div class=\"panel-group fusion-toggle-icon-unboxed\" id=\"accordion-4234-1\"><div class=\"fusion-panel panel-default panel-d71f3e0922f77d9d9 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_d71f3e0922f77d9d9\"><a aria-expanded=\"false\" aria-controls=\"d71f3e0922f77d9d9\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-1\" data-target=\"#d71f3e0922f77d9d9\" href=\"#d71f3e0922f77d9d9\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">What work is required?<\/span><\/a><\/h4><\/div><div id=\"d71f3e0922f77d9d9\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_d71f3e0922f77d9d9\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><span data-contrast=\"none\">Trurapi 3ml pre-filled pen devices are the best value, preferred insulin aspart pre-filled pen device in Dorset. In line with <\/span><a href=\"https:\/\/www.england.nhs.uk\/medicines-2\/biosimilar-medicines\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">NHSE recommendations<\/span><\/a><span data-contrast=\"none\">, PCN teams are asked to ensure that generic biosimilar insulin aspart accounts for at least 50% of all insulin aspart prescribing in primary care.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Clinical appropriateness should always be considered, and any switches should be discussed and agreed with patients through shared decision-making.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">Exclusion criteria:<\/span><\/b><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">< 18 years of age<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients prescribed\u00a0Fiasp\u00a0products (trurapi\u00a0is NOT interchangeable with\u00a0Fiasp\u00a0products)<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"3\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients prescribed\u00a0NovoRapid\u00a0FlexTouch pre-filled pen device<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"6\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients on insulin pumps<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients who are pregnant or planning to become pregnant<\/span><span data-ccp-props=\"\">\u00a0<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"12\" data-aria-level=\"1\"><span data-contrast=\"none\">Documented intolerance or allergy to any excipient listed in the\u00a0Trurapi\u00a0SPC or have failed\u00a0a previous\u00a0trial of\u00a0Trurapi<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"none\">Extra care should be taken when considering Truapi switch for patients:<\/span><\/p>\n<ul>\n<li><span data-contrast=\"none\">who have not had a HbA1c blood test or diabetes review in the last 12 months<\/span><\/li>\n<li>living with cognitive impairment, learning disability, dementia or Alzheimer's.<span data-ccp-props=\"{\">\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-1a48ba079ae32d03c fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_1a48ba079ae32d03c\"><a aria-expanded=\"false\" aria-controls=\"1a48ba079ae32d03c\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-1\" data-target=\"#1a48ba079ae32d03c\" href=\"#1a48ba079ae32d03c\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">Why is this part of the contract?<\/span><\/a><\/h4><\/div><div id=\"1a48ba079ae32d03c\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_1a48ba079ae32d03c\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Biosimilar insulin aspart (Trurapi) is now available in the UK and is significantly cheaper than Novorapid and generic originator insulin aspart products<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">A biosimilar medicine is a biological medicine which has been shown not to have any clinically meaningful differences from the originator medicine in terms of quality, safety and efficacy. Where NICE has already recommended the originator biological medicine, the same guidance applies to a biosimilar of that originator.\u00a0\u00a0NHS England aims to drive a step change in the uptake of biosimilar medicines by integrated care systems (ICS)<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Switching to insulin biosimilars will help PCN\u202fteams care for patients within their NHS England financial envelope and hence release funds to improve unmet needs in prevention.<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Early switching is recommended to maximise cumulative\u202fin year\u202fcost savings<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-3fcfeb41c09a6308f fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_3fcfeb41c09a6308f\"><a aria-expanded=\"false\" aria-controls=\"3fcfeb41c09a6308f\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-1\" data-target=\"#3fcfeb41c09a6308f\" href=\"#3fcfeb41c09a6308f\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">How do I do it?<\/span><\/a><\/h4><\/div><div id=\"3fcfeb41c09a6308f\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_3fcfeb41c09a6308f\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><span data-contrast=\"none\">Notify community pharmacy colleges of the intention to switch to Trurapi biosimilar prefilled pens.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Work with community pharmacy colleagues to ensure sufficient stock of\u00a0Trurapi\u00a0is available to support the switching programme and minimise disruption to patients,\u00a0GP\u00a0and community pharmacy teams.\u00a0<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Run the SystmOne searches provided to identify existing patients prescribed branded Novorapid and generic insulin aspart pre-filled pen products other than Trurapi.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Dorset SystmOne GPs>PINH 2627> 4a Biosimilar insulin>4c Work to do: T2DM with insulin aspart prefilled pens RPT consider switching to Trurapi biosimilar prefilled pens<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Dorset SystmOne GPs>PINH 2627> 4a Biosimilar insulin>4c Work to do: T1 diabetes with insulin aspart prefilled pens RPT\u00a0 consider switching to Trurapi biosimilar prefilled pens<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">A risk\u00a0<\/span><span data-contrast=\"none\">management<\/span><span data-contrast=\"none\">\u00a0<\/span><span data-contrast=\"none\">approach<\/span><span data-contrast=\"none\">\u00a0should be taken, to any batch-switching arrangement, which includes safeguards which enable patients to have a review, should they have any queries or changes to their condition.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Agree a patient-centred process for switching patients within the practice and convert patients accordingly.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Switch patients to the appropriate\u00a0Trurapi\u00a0device as below:<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n\n<div class=\"table-1\">\n<table width=\"100%\">\n<thead>\n<tr>\n<th align=\"left\"><span data-contrast=\"auto\">Originator insulin<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/th>\n<th align=\"left\"><span data-contrast=\"auto\">Switch to equivalent biosimilar insulin product<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td align=\"left\"><span data-contrast=\"auto\">NovoRapid\u00a0FlexPen\u00a0(insulin aspart 100units\/ml solution for injection) 3ml pre-filled pens<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<td align=\"left\"><span data-contrast=\"auto\">Prescribe\u00a0Trurapi\u00a0Solostar (insulin aspart 100units\/ml solution for injection) 3ml pre-filled pens<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<\/tr>\n<tr>\n<td align=\"left\"><span data-contrast=\"none\">Generic insulin aspart 100units\/ml solution for injection, 3ml pre-filled pens\u00a0<\/span><\/td>\n<td align=\"left\"><span data-contrast=\"auto\">Prescribe Trurapi Solostar (insulin aspart 100units\/ml solution for injection) 3ml pre-filled pens\u00a0<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n<p><span data-contrast=\"none\">Ensure all insulins including biosimilar insulins are prescribed by brand name and provide the strength or the provided insulin.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Switching a patient from\u00a0NovoRapid\u00a0to\u00a0Trurapi\u00a0can be done unit-to-unit based on the\u00a0previous\u00a0fast-acting insulin dose.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Patients should continue to\u00a0monitor\u00a0their blood glucose as usual and continue to use their current insulin needles.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Encourage patients to use up existing insulin supplies prior to starting their new biosimilar insulin.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Safety net the patient to report any concerns about glucose levels to the practice diabetes team.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Update the repeat prescription template and summary care record<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Update the patient's insulin passport.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">For further information and advice for healthcare professionals when starting treatment with a biosimilar, the\u00a0<\/span><span data-contrast=\"none\">MHRA has guidance on minimising the risk of medication error with high-strength, fixed combination and biosimilar insulin products<\/span><span data-contrast=\"none\">, which ensures the risk of medication errors with insulins is minimised. Biosimilar insulins are black triangle drugs. Report any suspected adverse effects to the MHRA via the Yellow Card reporting scheme\u00a0<\/span><a href=\"https:\/\/yellowcard.mhra.gov.uk\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Yellow Card | Making medicines and medical devices safer<\/span><\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Provide\u00a0appropriate counselling\u00a0where\u00a0appropriate.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p>Sanofi offer a pre-filled pen recycling programme. More information can be found here : <a href=\"https:\/\/www.mysanofiinsulin.co.uk\/repen\/\">RePen \u2013 | Sanofi Diabetes Patients Website<\/a><\/p>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-596de2bbfd0ee6a37 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_596de2bbfd0ee6a37\"><a aria-expanded=\"false\" aria-controls=\"596de2bbfd0ee6a37\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-1\" data-target=\"#596de2bbfd0ee6a37\" href=\"#596de2bbfd0ee6a37\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">What resources\/support is provided to help me deliver this?<\/span><\/a><\/h4><\/div><div id=\"596de2bbfd0ee6a37\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_596de2bbfd0ee6a37\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><strong>How to communicate this to patients:\u00a0<\/strong><\/p>\n<p><span data-contrast=\"none\">Use the template patient text message and letter in\u00a0SystmOne\u00a0to notify patients of the change. Ensure patient is counselled appropriately.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><strong>Patient text message:\u00a0<\/strong><\/p>\n<p><span data-contrast=\"none\">NovoRapid\u00a0FlexPen:<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">\"NHS Dorset have asked GP teams to review prescriptions for Novorapid Flexpens and switch to a new pen Trurapi Solostar. Trurapi Solostar pen is a biosimilar insulin and is the preferred insulin aspart in Dorset. Trurapi is considered clinically interchangeable with NovoRapid. The dosage will not change, and the insulin will work in the same way. Please use up your existing insulin supply prior to starting the new Trurapi solostar pen. Please read the patient information leaflet provided and if you have any questions regarding this change, please discuss with your community pharmacist or GP practice team\".<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><strong>Template patient letter:\u00a0<\/strong><\/p>\n<p><a href=\"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-content\/uploads\/sites\/3\/2026\/02\/Insulin-aspart-prefilled-pen-to-trurapi-template-letter.pdf\">Insulin aspart prefilled pen to trurapi template letter<\/a><\/p>\n<p><strong>References:\u00a0<\/strong><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.england.nhs.uk\/long-read\/what-is-a-biosimilar-medicine\/\"><span data-contrast=\"none\">NHS England \u00bb What is a biosimilar medicine?<\/span><\/a><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fnhsdorset.nhs.uk%2Fwp-content%2Fuploads%2F2025%2F04%2FBiosimilar-uptake-patient-letter-template-Jul24.docx&wdOrigin=BROWSELINK\">Biosimilar-uptake-patient-letter-template-Jul24.docx<\/a><\/p>\n<p><a href=\"https:\/\/www.mysanofiinsulin.co.uk\/trurapi\/\"><span data-contrast=\"none\">Trurapi\u00ae \u25be | Sanofi Diabetes Patients Website<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.mysanofiinsulin.co.uk\/trurapi\/downloads\/Trurapi\/Trurapi_SoloStar_Guide.pdf\"><span data-contrast=\"none\">Trurapi_SoloStar_Guide.pdf<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.mysanofiinsulin.co.uk\/repen\/\">RePen \u2013 | Sanofi Diabetes Patients Website<\/a><\/p>\n<p><a href=\"https:\/\/www.england.nhs.uk\/medicines-2\/biosimilar-medicines\/\"><span data-contrast=\"none\">NHS England \u00bb Biosimilar medicines<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.dorsetformulary.nhs.uk\/\"><span data-contrast=\"none\">NHS Dorset Biosimilar documents can be found on the front page of the Dorset Formulary<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.dorsetformulary.nhs.uk\/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.01.01.01&SubSectionID=C100&drugmatch=5994#5994\"><span data-contrast=\"none\">Dorset formulary<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/nhsdorset.nhs.uk\/Downloads\/aboutus\/medicines-management\/Other%20Guidelines\/Dorset%20Insulin%20Formulary%20for%20Type%201%20Type%202%20Diabetes%20in%20Adults%20Nov%2023.pdf?boxtype=pdf&g=false&s=true&s2=false&r=wide&UNLID=71293058420253311142\"><span data-contrast=\"none\">Dorset adult insulin formulary for type 1 & type 2 diabetes<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.nice.org.uk\/guidance\/ng17\/resources\/type-1-diabetes-in-adults-diagnosis-and-management-pdf-1837276469701\"><span data-contrast=\"none\">NICE NG17: type 1 diabetes in adults: diagnosis and management<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/type-2-diabetes-in-adults-management-pdf-1837338615493\"><span data-contrast=\"none\">NICE NG29: type 2 diabetes in adults: management<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error?UNLID=7533607272016481362\"><span data-contrast=\"none\">MHRA (2015): High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-62dfe54db2665d609 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_62dfe54db2665d609\"><a aria-expanded=\"false\" aria-controls=\"62dfe54db2665d609\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-1\" data-target=\"#62dfe54db2665d609\" href=\"#62dfe54db2665d609\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">How do I calculate my progress against the target for this metric<\/span><\/a><\/h4><\/div><div id=\"62dfe54db2665d609\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_62dfe54db2665d609\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p>Tracking achievement:<\/p>\n<p>Numerator divided by Denominator from SystmOne searches x 100 for %<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1310.4px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-2\"><p><span class=\"TextRun SCXW79299778 BCX8\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"none\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW79299778 BCX8\">Trurapi<\/span><span class=\"NormalTextRun SCXW79299778 BCX8\"> biosimilar as the best value preferred insulin aspart cartridge.\u00a0 Switches to be completed in clinic as part of scheduled diabetes review. New disposable pen device to be provided during review.<\/span><\/span><\/p>\n<\/div><div class=\"accordian fusion-accordian\" style=\"--awb-border-size:1px;--awb-icon-size:18px;--awb-content-font-size:var(--awb-typography4-font-size);--awb-icon-alignment:left;--awb-hover-color:var(--awb-color2);--awb-border-color:var(--awb-color3);--awb-background-color:var(--awb-color1);--awb-divider-color:var(--awb-color3);--awb-divider-hover-color:var(--awb-color3);--awb-icon-color:var(--awb-color5);--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);--awb-icon-box-color:var(--awb-color5);--awb-toggle-hover-accent-color:var(--awb-color4);--awb-toggle-active-accent-color:var(--awb-color4);--awb-title-font-family:var(--awb-typography1-font-family);--awb-title-font-weight:var(--awb-typography1-font-weight);--awb-title-font-style:var(--awb-typography1-font-style);--awb-title-font-size:20px;--awb-content-font-family:var(--awb-typography4-font-family);--awb-content-font-weight:var(--awb-typography4-font-weight);--awb-content-font-style:var(--awb-typography4-font-style);\"><div class=\"panel-group fusion-toggle-icon-unboxed\" id=\"accordion-4234-2\"><div class=\"fusion-panel panel-default panel-01d316707fd461f7a fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_01d316707fd461f7a\"><a aria-expanded=\"false\" aria-controls=\"01d316707fd461f7a\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-2\" data-target=\"#01d316707fd461f7a\" href=\"#01d316707fd461f7a\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">What work is required?<\/span><\/a><\/h4><\/div><div id=\"01d316707fd461f7a\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_01d316707fd461f7a\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><span data-contrast=\"none\">Trurapi\u00a0is the best value, preferred insulin aspart product in Dorset. In line with\u00a0<\/span><a href=\"https:\/\/www.england.nhs.uk\/medicines-2\/biosimilar-medicines\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">NHSE recommendations<\/span><\/a><span data-contrast=\"none\">, PCN teams are asked to ensure that generic biosimilar insulin aspart accounts for at least 50% of all insulin aspart prescribing in primary care.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Clinical appropriateness should always be considered, and any switches should be discussed and agreed with patients through shared decision-making.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">Exclusion criteria:<\/span><\/b><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">< 18 years of age<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients prescribed\u00a0Fiasp\u00a0products (trurapi\u00a0is NOT interchangeable with\u00a0Fiasp\u00a0products)<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients prescribed\u00a0NovoRapid\u00a0PumpCart\u00a01.6ml cartridges<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients on insulin pumps<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients who are pregnant or planning to become pregnant<\/span><span data-ccp-props=\"\">\u00a0<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Patients who use a smart insulin pen device with their insulin cartridges<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Documented intolerance or allergy to any excipient listed in the\u00a0Trurapi\u00a0SPC or have failed\u00a0a previous\u00a0trial of\u00a0Trurapi<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"none\">Extra care should be taken when considering Truapi switch for patients:<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"11\" data-aria-level=\"1\"><span data-contrast=\"none\">who have not had a HbA1c blood test or diabetes review in the last 12 months<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"18\" data-list-defn-props=\"{\" data-aria-posinset=\"11\" data-aria-level=\"1\">living with cognitive impairment, learning disability, dementia or Alzheimer's.<span data-ccp-props=\"{\">\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-3904b5e950c231760 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_3904b5e950c231760\"><a aria-expanded=\"false\" aria-controls=\"3904b5e950c231760\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-2\" data-target=\"#3904b5e950c231760\" href=\"#3904b5e950c231760\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">Why is this part of the contract?<\/span><\/a><\/h4><\/div><div id=\"3904b5e950c231760\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_3904b5e950c231760\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Biosimilar insulin aspart (Trurapi) is now available in the UK and is significantly cheaper than Novorapid and generic originator insulin aspart products<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">A biosimilar medicine is a biological medicine which has been shown not to have any clinically meaningful differences from the originator medicine in terms of quality, safety and efficacy. Where NICE has already recommended the originator biological medicine, the same guidance applies to a biosimilar of that originator.\u00a0\u00a0NHS England aims to drive a step change in the uptake of biosimilar medicines by integrated care systems (ICS)<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Switching to insulin biosimilars will help PCN\u202fteams care for patients within their NHS England financial envelope and hence release funds to improve unmet needs in prevention.<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"19\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">Early switching is recommended to maximise cumulative\u202fin year\u202fcost savings<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-3a45688d584423d66 fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_3a45688d584423d66\"><a aria-expanded=\"false\" aria-controls=\"3a45688d584423d66\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-2\" data-target=\"#3a45688d584423d66\" href=\"#3a45688d584423d66\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">How do I do it?<\/span><\/a><\/h4><\/div><div id=\"3a45688d584423d66\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_3a45688d584423d66\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><span data-contrast=\"none\">Notify community pharmacy colleges of the intention to switch to Trurapi biosimilar cartridges.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Work with community pharmacy colleagues to ensure sufficient stock of\u00a0Trurapi\u00a0is available to support the switching programme and minimise disruption to patients,\u00a0GP\u00a0and community pharmacy teams.\u00a0<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Patients using insulin aspart cartridges will require a <strong>new reusable pen device<\/strong> when switching to Trurapi. Pens can be ordered direct from Sanofi into GP practices. It is therefore recommended that patients are switched opportunistically to Trurapi cartridges as part of standard diabetes reviews. Reusable pens can be ordered into GP practices in advance and given to patients at the time of prescribing Trurapi cartridges. <\/span><\/p>\n<p><span data-contrast=\"none\">Check patients get the intended insulin with the correct delivery device for that insulin and are trained on how to use it.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Trurapi\u00a0cartridges should only be used with the following pens:<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"21\" data-list-defn-props=\"{\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">JuniorSTAR which delivers\u00a0Trurapi\u00a0in\u00a00.5 unit\u00a0dose increments<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"21\" data-list-defn-props=\"{\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"none\">Allstar PRO which delivers\u00a0Trurapi\u00a0in 1 unit dose increments<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"none\">Contact Sanofi 0800 035 2525 for supplies of durable pens and patient information leaflets prior to converting patients to Trurapi.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Run the\u00a0SystmOne\u00a0<\/span><span data-contrast=\"none\">searches provided to identify existing patients prescribed branded Novorapid and generic insulin aspart cartridges and consider switch to Trurapi:<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Dorset SystmOne GPs>PINH 2627> 4a Biosimilar insulin>4c Work to do: T2DM with Insulin aspart cartridges RPT consider switching to Trurapi biosimilar cartridges<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Dorset SystmOne GPs>PINH 2627> 4a Biosimilar insulin>4c Work to do: T1 diabetes with Insulin aspart cartridges RPT consider switching to Trurapi biosimilar cartridges<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Agree a patient-centred process for switching patients within the practice and convert patients accordingly.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Switch patients to the appropriate\u00a0Trurapi\u00a0device as below:<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n\n<div class=\"table-1\">\n<table style=\"height: 154px\" width=\"1134\">\n<thead>\n<tr>\n<th align=\"left\"><span data-contrast=\"auto\">Originator insulin<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/th>\n<th align=\"left\"><span data-contrast=\"auto\">Switch to equivalent biosimilar insulin product<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td align=\"left\"><span data-contrast=\"none\">NovoRapid\u00a0Penfill\u00a0(insulin aspart 100units\/ml solution for injection) 3ml\u00a0<\/span><span data-contrast=\"none\">cartridges<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<td align=\"left\"><span data-contrast=\"none\">Trurapi\u00a0(insulin aspart 100units\/ml solution for injection) 3ml cartridges<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<\/tr>\n<tr>\n<td align=\"left\"><span data-contrast=\"none\">Generic insulin aspart 100units\/ml solution for injection, s OR 3ml cartridges<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<td align=\"left\"><span data-contrast=\"auto\">Prescribe\u00a0 Trurapi (insulin aspart 100units\/ml solution for injection) 3ml cartridges<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/td>\n<\/tr>\n<tr>\n<td align=\"left\"><\/td>\n<td align=\"left\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n<p><span data-contrast=\"none\">Ensure all insulins including biosimilar insulins are prescribed by brand name and provide the strength or the provided insulin.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Switching a patient from\u00a0NovoRapid\u00a0to\u00a0Trurapi\u00a0can be done unit-to-unit based on the\u00a0previous\u00a0fast-acting insulin dose.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Patients should continue to\u00a0monitor\u00a0their blood glucose as usual and continue to use their current insulin needles.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Encourage patients to use up existing insulin supplies prior to starting their new biosimilar insulin.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Safety net the patient to report any concerns about glucose levels to the practice diabetes team.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Update the repeat prescription template and summary care record<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Update the patient's insulin passport.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">For further information and advice for healthcare professionals when starting treatment with a biosimilar, the\u00a0<\/span><span data-contrast=\"none\">MHRA has guidance on minimising the risk of medication error with high-strength, fixed combination and biosimilar insulin products<\/span><span data-contrast=\"none\">, which ensures the risk of medication errors with insulins is minimised. Biosimilar insulins are black triangle drugs. Report any suspected adverse effects to the MHRA via the Yellow Card reporting scheme\u00a0<\/span><a href=\"https:\/\/yellowcard.mhra.gov.uk\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Yellow Card | Making medicines and medical devices safer<\/span><\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Provide\u00a0appropriate counselling\u00a0where\u00a0appropriate.<\/span><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-18bf20047aed0b9ec fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_18bf20047aed0b9ec\"><a aria-expanded=\"false\" aria-controls=\"18bf20047aed0b9ec\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-2\" data-target=\"#18bf20047aed0b9ec\" href=\"#18bf20047aed0b9ec\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">What resources\/support is provided to help me deliver this?<\/span><\/a><\/h4><\/div><div id=\"18bf20047aed0b9ec\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_18bf20047aed0b9ec\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p><strong>How to communicate this to patients:\u00a0<\/strong><\/p>\n<p><span data-contrast=\"none\">Use the template patient text message and letter in\u00a0SystmOne\u00a0to notify patients of the change. Ensure patient is counselled appropriately.<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><strong>Patient text message:\u00a0<\/strong><\/p>\n<p><strong>NovoRapid\u00a0cartridges:\u00a0<\/strong><\/p>\n<p><span data-contrast=\"none\">\"NHS Dorset have asked GP teams to review prescriptions for Novorapid Cartridges and switch to a new cartridge Trurapi. Trurapi is a biosimilar insulin and is the preferred insulin aspart in Dorset. Trurapi is considered clinically interchangeable with NovoRapid. The dosage will not change, and the insulin will work in the same way. Please use up your existing insulin supply prior to starting the new Trurapi cartridges. To administer the Trurapi, you will require a new insulin pen, this will be provided to you with instructions for how to use this. Please read the patient information leaflet provided and if you have any questions regarding this change, please discuss with your community pharmacist or GP practice team\".<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><strong>Template patient letter:\u00a0<\/strong><\/p>\n<p><a href=\"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-content\/uploads\/sites\/3\/2026\/02\/Insulin-aspart-CARTRIDGES-pateint-template-letter.pdf\">Insulin aspart CARTRIDGES patient template letter<\/a><\/p>\n<p><span data-contrast=\"none\">How to\u00a0monitor\u00a0progress:<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Volume of patients switched to best value will be published within the DiiS Prescribing Improvement in Neighbourhood Health 26 27 dashboard<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><strong>References:\u00a0<\/strong><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.england.nhs.uk\/long-read\/what-is-a-biosimilar-medicine\/\"><span data-contrast=\"none\">NHS England \u00bb What is a biosimilar medicine?<\/span><\/a><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.mysanofiinsulin.co.uk\/trurapi\/\"><span data-contrast=\"none\">Trurapi\u00ae \u25be | Sanofi Diabetes Patients Website<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fnhsdorset.nhs.uk%2Fwp-content%2Fuploads%2F2025%2F04%2FBiosimilar-uptake-patient-letter-template-Jul24.docx&wdOrigin=BROWSELINK\">Biosimilar-uptake-patient-letter-template-Jul24.docx<\/a><\/p>\n<p><a href=\"https:\/\/www.england.nhs.uk\/medicines-2\/biosimilar-medicines\/\"><span data-contrast=\"none\">NHS England \u00bb Biosimilar medicines<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.dorsetformulary.nhs.uk\/\"><span data-contrast=\"none\">NHS Dorset Biosimilar documents can be found on the front page of the Dorset Formulary<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.dorsetformulary.nhs.uk\/chaptersSubDetails.asp?FormularySectionID=6&SubSectionRef=06.01.01.01&SubSectionID=C100&drugmatch=5994#5994\"><span data-contrast=\"none\">Dorset formulary<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/nhsdorset.nhs.uk\/Downloads\/aboutus\/medicines-management\/Other%20Guidelines\/Dorset%20Insulin%20Formulary%20for%20Type%201%20Type%202%20Diabetes%20in%20Adults%20Nov%2023.pdf?boxtype=pdf&g=false&s=true&s2=false&r=wide&UNLID=71293058420253311142\"><span data-contrast=\"none\">Dorset adult insulin formulary for type 1 & type 2 diabetes<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.nice.org.uk\/guidance\/ng17\/resources\/type-1-diabetes-in-adults-diagnosis-and-management-pdf-1837276469701\"><span data-contrast=\"none\">NICE NG17: type 1 diabetes in adults: diagnosis and management<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/type-2-diabetes-in-adults-management-pdf-1837338615493\"><span data-contrast=\"none\">NICE NG29: type 2 diabetes in adults: management<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error?UNLID=7533607272016481362\"><span data-contrast=\"none\">MHRA (2015): High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error<\/span><\/a><span data-ccp-props=\"{\">\u00a0<\/span><span data-ccp-props=\"\">\u00a0<\/span><\/p>\n<\/div><\/div><\/div><div class=\"fusion-panel panel-default panel-833f92945f432ef4f fusion-toggle-no-divider fusion-toggle-boxed-mode\" style=\"--awb-title-color:var(--awb-color5);--awb-content-color:var(--awb-custom_color_1);\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\" id=\"toggle_833f92945f432ef4f\"><a aria-expanded=\"false\" aria-controls=\"833f92945f432ef4f\" role=\"button\" data-toggle=\"collapse\" data-parent=\"#accordion-4234-2\" data-target=\"#833f92945f432ef4f\" href=\"#833f92945f432ef4f\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box active-icon awb-icon-minus\" aria-hidden=\"true\"><\/i><i class=\"fa-fusion-box inactive-icon fa-capsules fas\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">How do I calculate my progress against the target for this metric<\/span><\/a><\/h4><\/div><div id=\"833f92945f432ef4f\" class=\"panel-collapse collapse \" aria-labelledby=\"toggle_833f92945f432ef4f\"><div class=\"panel-body toggle-content fusion-clearfix\">\n<p>Tracking achievement:<\/p>\n<p>Numerator divided by Denominator from SystmOne searches x 100 for %<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":3067,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-4234","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/pages\/4234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/comments?post=4234"}],"version-history":[{"count":25,"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/pages\/4234\/revisions"}],"predecessor-version":[{"id":4525,"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/pages\/4234\/revisions\/4525"}],"up":[{"embeddable":true,"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/pages\/3067"}],"wp:attachment":[{"href":"https:\/\/nhsdorset.nhs.uk\/medicines\/wp-json\/wp\/v2\/media?parent=4234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}